0001104659-23-122840.txt : 20231201
0001104659-23-122840.hdr.sgml : 20231201
20231201161602
ACCESSION NUMBER: 0001104659-23-122840
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231201
FILED AS OF DATE: 20231201
DATE AS OF CHANGE: 20231201
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mehra Raj
CENTRAL INDEX KEY: 0001757892
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22245
FILM NUMBER: 231459723
MAIL ADDRESS:
STREET 1: C/O SEELOS THERAPEUTICS, INC.
STREET 2: 300 PARK AVENUE, 12TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SEELOS THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001017491
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 870449967
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 PARK AVENUE
STREET 2: 2ND FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: (646) 293-2100
MAIL ADDRESS:
STREET 1: 300 PARK AVENUE
STREET 2: 2ND FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
FORMER COMPANY:
FORMER CONFORMED NAME: APRICUS BIOSCIENCES, INC.
DATE OF NAME CHANGE: 20100914
FORMER COMPANY:
FORMER CONFORMED NAME: NEXMED INC
DATE OF NAME CHANGE: 19970311
4
1
tm2331921-1_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2023-12-01
0
0001017491
SEELOS THERAPEUTICS, INC.
SEEL
0001757892
Mehra Raj
C/O SEELOS THERAPEUTICS, INC.
300 PARK AVENUE, 2ND FLOOR
NEW YORK
NY
10022
1
1
0
0
See Remarks
0
Common Stock
2023-12-01
4
P
0
75757
1.32
A
185142
D
Common Stock Warrant (right to buy)
1.32
2023-12-01
4
P
0
75757
A
2023-12-01
2028-12-01
Common Stock
75757
75757
D
Each share of common stock was purchased together with an accompanying warrant to purchase one share of common stock in an underwritten public offering at a combined offering price of $1.32 per share of common stock and accompanying warrant.
Effective on November 28, 2023, the Issuer conducted a reverse stock split at a ratio of 1-for-30 (the "Reverse Split"). The number of shares reported herein reflects the number of shares after the Reverse Split.
President, Chief Executive Officer and Chairman of the Board of Directors
/s/ Raj Mehra
2023-12-01